Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Ines Kleiber"'
Autor:
Andrew E. Aplin, Reinhard Dummer, Mitch P. Levesque, Lawrence N. Kwong, Michael A. Davies, Kim HooKim, Ines Kleiber, Paolo M. Fortina, Adam Ertel, Inna Chervoneva, Prem Patel, Neda Nikbakht, Timothy J. Purwin, Phil F. Cheng, Jessica L.F. Teh
Targeting cyclin-dependent kinases 4/6 (CDK4/6) represents a therapeutic option in combination with BRAF inhibitor and/or MEK inhibitor (MEKi) in melanoma; however, continuous dosing elicits toxicities in patients. Using quantitative and temporal in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::279be8361973204419e794552ad613e1
https://doi.org/10.1158/2159-8290.c.6546826
https://doi.org/10.1158/2159-8290.c.6546826
Autor:
Andrew E. Aplin, Reinhard Dummer, Mitch P. Levesque, Lawrence N. Kwong, Michael A. Davies, Kim HooKim, Ines Kleiber, Paolo M. Fortina, Adam Ertel, Inna Chervoneva, Prem Patel, Neda Nikbakht, Timothy J. Purwin, Phil F. Cheng, Jessica L.F. Teh
Supplementary Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::698fa26e54d1b25e6754191d77b3896e
https://doi.org/10.1158/2159-8290.22532773.v1
https://doi.org/10.1158/2159-8290.22532773.v1
Autor:
Andrew E. Aplin, Reinhard Dummer, Mitch P. Levesque, Lawrence N. Kwong, Michael A. Davies, Kim HooKim, Ines Kleiber, Paolo M. Fortina, Adam Ertel, Inna Chervoneva, Prem Patel, Neda Nikbakht, Timothy J. Purwin, Phil F. Cheng, Jessica L.F. Teh
Materials and Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50b68f1233deff5cefbba188594d7f17
https://doi.org/10.1158/2159-8290.22532770
https://doi.org/10.1158/2159-8290.22532770
Autor:
Inna Chervoneva, Reinhard Dummer, Phil F. Cheng, Mitch Levesque, Neda Nikbakht, Timothy J. Purwin, Michael A. Davies, Jessica L.F. Teh, Lawrence N. Kwong, Adam Ertel, Ines Kleiber, Prem Patel, Paolo Fortina, Andrew E. Aplin, Kim HooKim
Publikováno v:
Cancer Discovery. 8:568-581
Targeting cyclin-dependent kinases 4/6 (CDK4/6) represents a therapeutic option in combination with BRAF inhibitor and/or MEK inhibitor (MEKi) in melanoma; however, continuous dosing elicits toxicities in patients. Using quantitative and temporal in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c5ffcb2dc25b52dd2a6423acad8ac2a
https://doi.org/10.1158/2159-8290.cd-17-0699
https://doi.org/10.1158/2159-8290.cd-17-0699
Autor:
Jessica L F, Teh, Phil F, Cheng, Timothy J, Purwin, Neda, Nikbakht, Prem, Patel, Inna, Chervoneva, Adam, Ertel, Paolo M, Fortina, Ines, Kleiber, Kim, HooKim, Michael A, Davies, Lawrence N, Kwong, Mitch P, Levesque, Reinhard, Dummer, Andrew E, Aplin
Publikováno v:
Cancer discovery. 8(12)
Targeting cyclin-dependent kinases 4/6 (CDK4/6) represents a therapeutic option in combination with BRAF inhibitor and/or MEK inhibitor (MEKi) in melanoma; however, continuous dosing elicits toxicities in patients. Using quantitative and temporal in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9e1604ac9f77bb712d039dc62ebece1c
https://pubmed.ncbi.nlm.nih.gov/29496664
https://pubmed.ncbi.nlm.nih.gov/29496664
Autor:
Andrew E. Aplin, Kim HooKim, Neda Nikbakht, Jessica L.F. Teh, Lawrence N. Kwong, Adam Ertel, Ines Kleiber, Michael A. Davies, Prem Patel, Timothy J. Purwin, Paolo Fortina, Phil F. Cheng, Reinhard Dummer, Mitch Levesque, Inna Chervoneva
Publikováno v:
Cancer Discovery. 8:1654-1654
In the original version of [this article][1] ([1][2]), an error in Fig. 6C was introduced by the compositor during the production of the paper. Specifically, the Raptor Western blot was improperly shifted. The figure has been corrected in the latest
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2ff1d1963e589c5e99d11ea9307463aa
https://doi.org/10.1158/2159-8290.cd-18-1291
https://doi.org/10.1158/2159-8290.cd-18-1291